AGA Clinical Practice Update on the Evaluation and Management of Metabolic Dysfunction– and Alcohol-Associated Liver Disease: Expert Review

Study limitation reported by the research below: “FDA-approved MASLD therapies (resmetirom, semaglutide) have not been studied in MetALD-specific trials; the GLP-1/GIP data on alcohol craving reduction is described as preliminary only.”